MEDIDATA GmbH CRO for Phase II to Phase IV Clinical TrialsMEDIDATA GmbH is a contract research organisation (CRO) that has been providing end-to-end services for phase II to phase IV clinical trials and for observational studies for more than 25 years.>Clinical Trials>Suppliers
The Toxikon Europe Screener Database TOX-RAY : a Powerful Tool for the Identification of Organic Compounds During Controlled Extraction StudiesPublished by Toxikon Europe PBR>Clinical Trials>White Papers
The international multicenter randomized double-blind placebo-controlled CORRECT study enrolled 760 patients with metastatic colorectal cancer (mCRC) whose disease had progressed during or within 3 months following last administration of approved standard therapie.
Asterand - Human Tissue and Human Tissue-Based Research ServicesAsterand plc is the leading global supplier of high quality, well characterised human tissue and human tissue-based research services to drug discovery scientists.>Clinical Trials>Suppliers
Contract Research & Services>Clinical Trials
Related Sectors
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
Marketing Authorisation Procedures in the European Union Making the Right ChoicePublished by SGS PBR>Clinical Trials>White Papers
Stromal tumor Bayer Regorafenib meets CORRECT trial endpoints,Regorafenib is an investigational oral multi-kinase inhibitor targeting angiogenic, stromal and oncogenic kinases and is currently being evaluated in clinical trials for its potential to treat patients with various tumor types.
Future of Cardiovascular Drug DevelopmentPublished by Centre for Human Drug Research>Clinical Trials>White Papers
2012>January
Contract Research & ServicesContract Services
The study demonstrated that the drug met its primary endpoint, showing 29% improvement in overall survival (OS), and also met secondary endpoints showing improvement in progression-free survival (PFS) and disease control rate in mCRC patients treated with Regorafenib.
In tStromal tumor Bayer Regorafenib meets CORRECT trial endpointshe trial, patients were randomized to receive either regorafenib plus best supportive care (BSC) or placebo plus BSC.
Bayer plans to submit Regorafenib for marketing authorization in mCRC this year.
Bayers investigational compound Regorafenib (BAY 73-4506) has met all the endpoints in the Phase 3 Colorectal cancer treated with regorafenib or placebo after ilure of standard therapy (CORRECT) trial.
Multipharma - Global Clinical Trial Supply and Comparator Drug SourcingSpecialising in comparator drug sourcing activities while supporting the industrys global clinical supply chain.>Clinical Trials>Suppliers
Related Industries
Regulatory Afirs
Toxikon Europe - Preclinical Safety Studies and QC Testing for the Life Science CommunityFor more than 30 years Toxikon has been a leading contract research organisation (CRO) providing high-quality preclinical safety studies to the life science community.>Clinical Trials>Suppliers
The Informed Design and Validation of Quality of Life Questionnaires and Rating Scales Using Rasch AnalysisPublished by Exploristics>Clinical Trials>White Papers
GBI Research, the leading business intelligence provider, has released its latest report, Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Researchs team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a ster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D cility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity.Buy online from &36;3500
Pharmaceuticals and Healthcare>Services>Outsourced Services>Contract Research Organization>Clinical trials
In 2011, Bayer and Onyx signed an agreement, under which Onyx will receive a royalty on any future global net sales of Regorafenib in oncology.
Related Dates
Drug ResearchDrug Discovery & Development
Production & ManucturingOTC
AutomationLaboratory Instrumentation
